Survival prediction with neuroendocrine differentiation?

摘要

Wu cautions that the data are not applicable to clinical decision making, since their results were based on the observation of effects after che-moradiotherapy that might not be applicable to predicting chemorad-iotherapy effects. "In addition, pretreatment tumour "sampling error" could result in false negatives if only a small proportion of tumours contains neuroendocrine differentiation", Wu comments."Chemoradiotherapy together with therapies targeted at neuroendocrine differentiation of tumour cells could improve prognosis for adenocarcinoma of the oesophagogastric junction", says Herman van Dekken (Erasmus Medical Center, Rotterdam, Holland).